2022-500395-57-00RecruitingPhase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
Merck Sharp & Dohme Corp.55 sites in 11 countries267 target enrollmentStarted: January 18, 2023Last updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Merck Sharp & Dohme Corp.
- Enrollment
- 267
- Locations
- 55
- Primary Endpoint
- Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
Study Overview
Brief Summary
To compare the recurrence-free survival (RFS), as assessed by the investigator and confirmed by biopsy, in individuals who receive pembrolizumab with individuals who receive placebo as adjuvant therapy.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Has histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy (metastatic skin involvement from another type of primary cancer or from an unknown primary cancer is not permitted)
- •Has provided an archival or newly-obtained tumor tissue sample adequate for Programmed Cell Death Ligand 1 (PD-L1) testing as determined by central laboratory testing
- •Has a life expectancy of >3 months
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ≤10 days prior to the first dose of study intervention
- •Has histologically confirmed LA cSCC with ≥1 high-risk feature(s) as the primary site of malignancy
- •Has undergone complete macroscopic resection of all known cSCC disease with or without microscopic positive margins. For those participants with residual microscopic positive margin involvement, confirmation that additional re-excision is not possible must be provided
- •Has completed adjuvant radiotherapy (RT) for LA cSCC with last dose of RT ≥4 weeks and ≤16 weeks from randomization
- •Has received an adequate post-op dose of RT (either hypofractionated or conventional)
- •Is disease free as assessed by the investigator with complete radiographic staging assessment ≤28 days from randomization
- •Is not pregnant or breastfeeding
- •Is not a person of childbearing potential (POCBP)
- •Has a negative pregnancy test ≤72 hours before the first dose of study intervention
Exclusion Criteria
- •Has macroscopic residual cSCC after surgery and/or recurrence with active cSCC disease before randomization
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •Has an active infection requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection
- •Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV; defined as HCV RNA [qualitative] is detected) infection
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
- •Has had an allogeneic tissue/solid organ transplant
- •Has any other histologic type of skin cancer other than invasive cSCC (eg, basal cell carcinoma) that has not been definitively treated with surgery or radiation; Bowen’s disease; Merkel cell carcinoma; or melanoma
- •Has received prior therapy with an anti-programmed cell death receptor 1(PD-1), anti- PD-L1, or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another co-stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
- •Has received prior systemic anticancer therapy including investigational agents for cSCC ≤4 weeks prior to before start of study intervention
- •Has not recovered from all radiation-related toxicities and has not had radiation pneumonitis
- •Has received a live vaccine ≤30 days prior to the first dose of study intervention
- •Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- •Has known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Other exceptions may be considered with Sponsor consultation. Note: Participants with low risk early-stage prostate cancer defined as below are not excluded: Stage T1c or T2a with a Gleason score ≤6 and a prostate-specific antigen (≤10 ng/ml) either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation. Early stage asymptomatic CLL without prior treatment and without any of the risk features (unmutated IGHV, lymphocytes >15,000μL, palpable lymph nodes) will be eligible for the study
- •Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid
Outcomes
Primary Outcomes
Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
Secondary Outcomes
- Overall Survival (OS)
- Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score
- Change From Baseline in Physical Functioning Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1-5 Score
- Percentage of Participants Who Experience an Adverse Event (AE)
- Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Investigators
Jianda Yuan
Scientific
Merck Sharp & Dohme Corp.
Study Sites (55)
Loading locations...
Similar Trials
Recruiting
Phase 4
Complete Remission After Treatment With Biologics for Nasal PolypsNCT07268313Rigshospitalet, Denmark66
Recruiting
Phase 3
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
Recruiting
Phase 3
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
Completed
Phase 1
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.NCT07272629Sanofi48